XTL Biopharmaceuticals Establishes U.S. Operations / Glenn Kazo Appointed Vice President, Business Development and General Manager -

Rehovot, Israel and New Ipswich, N.H. (PROTEXT) - XTL Biopharmaceuticals, Ltd. announced today the establishment of a subsidiary, XTL Biopharmaceuticals, Inc., with operations based in New Hampshire (United States). Glenn M. Kazo has been appointed Vice President of Business Development and General Manager of Company operations in the United States. "XTL's establishment of a firm foothold in the U.S. will facilitate direct access to the world's largest market for pharmaceutical- and biotechnology- based products," stated Martin Becker, Ph.D., President and Chief Executive Officer of XTL. "Our operations in the U.S. will support XTL's business development activities and will lay the foundation for efficient introduction of XTL's product candidates into the American regulatory environment. Furthermore, we are pleased to welcome Glenn, and his broad range of expertise in the biopharmaceutical industry, to our team." Prior to joining XTL, Mr. Kazo served as Vice President, Corporate Development at Focal, Inc., a public medical device firm in Lexington, MA. Additionally, he was a founding member of Enzon, Inc., a leading drug delivery company, where he pioneered the development of two of the company's marketed drug products. Mr. Kazo's expertise ranges from technical pharmaceutical product development to business development, licensing, mergers and acquisitions, finance, sales and marketing, communications and operations. Mr. Kazo has over 15 years of experience in business development, strategic planning and general management for the biopharmaceutical industry, and he has managed a consulting practice focusing on emerging technologies. XTL has recently initiated a Phase I study of XTL001, an investigational monoclonal antibody (MAb) product, to evaluate the safety profile and antiviral activity of the compound in patients chronically infected with hepatitis B virus (HBV). The Company has also signed an agreement to test an Eli Lilly & Company drug candidate in XTL's proprietary animal model for hepatitis C (HCV). The Trimera(XTL) system is a breakthrough, patented method, which enables a mouse to carry human liver fragments infected with HCV, thus offering the potential to biologically validate the effectiveness of drug candidates before embarking on costly human clinical studies. For further information on XTL Biopharmaceuticals, Inc., please contact Glenn Kazo at (603) 878 9857. XTL is a biopharmaceutical company developing fully human monoclonal antibody-based therapeutics with a primary focus on infectious diseases. The Company applies its proprietary drug discovery and development "engine," the Trimera(XTL) system, to produce high affinity, fully human antibodies to a broad range of disease targets including hepatitis B (HBV) and hepatitis C (HCV). In addition, XTL has unique, high-value animal models of human diseases including models for testing HBV and HCV therapeutic drugs. For more information about XTL, visit the Company's website at http://www.xtlbio.com. ots Original Text Service: XTL Biopharmaceuticals, Ltd. Internet: http://www.newsaktuell.de Contact: Glenn Kazo, Vice President, Business Development and General Manager of XTL Biopharmaceuticals, Inc., (USA) 603-878-9857, or gkazo@xtlbio.com, or in Israel: Martin Becker, Ph.D., President and CEO of XTL Biopharmaceuticals, Ltd., +972-8-940-5134, or becker@xtlbio.com; or Douglas MacDougall or Kari Lampka, both of Feinstein Kean Partners Inc. (USA) 617-577-8110, for XTL Biopharmaceuticals Web site: http://www.xtlbio.com Subscribers please note that material bearing the slug "PROTEXT" is not part of CTK's news service and is not to be published under the "CTK" slug. Protext is a commercial service providing distribution of press releases from clients, who are identified in the text of Protext reports and who bear full responsibility for their contents. PROTEXT